Poster Presentations: Clinical: Therapy and Observation 2023

P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis

P377 Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn's disease

P378 Pharmacokinetics of Vedolizumab and Ustekinumab in pregnant women with Inflammatory Bowel Disease and their infants exposed in-utero

P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies

P380 Changes in faecal microbiome and metabolome are more pronounced in Crohn’s disease patients who adhered to the CD-TREAT diet and responded by calprotectin.

P381 Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease

P382 Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's Disease

P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.

P384 A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn’s Disease: first results of a prospective cohort

P385 Risk-benefit assessment of IBD drugs: a physicians and patients survey

P386 Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.

P387 Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease

P388 Shear wave elastography predicts short-term response to induction therapy in patients with Crohn’s disease

P389 Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) – A prospective, real-world, single centre, phase IV interventional study.

P390 Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapy

P391 Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with mod

P392 Risk factors for postoperative recurrence after ileocolic resection for Crohn’s Disease: long-term results from a population-based cohort.

P393 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION

P394 Long-term perineal reoperation and wound healing after proctectomy or ileal pouch-anal anastomosis extirpation in patients with Inflammatory Bowel Disease – a retrospective multicentre study

P395 Short-term clinical efficacy and safety of teduglutide for Crohn’s disease patients with short bowel syndrome

P396 Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn’s Disease

P397 Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)

P398 Disease clearance: a potential target for management of patients with Ulcerative Colitis

P399 Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?

P400 Identifying Nutritional targets in Crohn’s disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remission

P401 Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative Colitis

P402 A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn’s Disease

P403 Therapeutic compliance in patients with chronic inflammatory bowel disease.

P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission

P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension

P406 Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim Analysis

P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

P408 Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

P409 Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluation

P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA

P411 Early ultrasound assessment predicts therapy response: an easy tool for clinical decision making

P412 Time trend in clinicopathological features and prognosis of Ulcerative Colitis associated neoplasia: A nationwide cohort in Japan

P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

P414 Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study

P415 Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II study

P416 The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.

P417 Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Stud

P418 Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.

P419 Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative Colitis

P420 Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn’s Disease

P421 Real-world effectiveness and safety of vedolizumab induction therapy for Crohn’s disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes

P422 Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease

P423 Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis

P424 Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?

P425 The utility of intestinal ultrasound to inform clinical decision making

P426 Sex and sexuality in IBD - the pediatric gastroenterologists’ point of view

P427 One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn’s Disease

P428 Pharmacist led clinic in Inflammatory Bowel Disease

P429 Patient skeletal muscle area and postoperative clinical recurrence in Crohn’s disease: a retrospective study

P430 Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remission

P431 A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence

P432 Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemic

P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease

P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials

P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study

P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial

P437 Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .

P438 Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extension

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

P440 Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis

P441 Long-term CD treatment failure and dose modification rates with vedolizumab and other biologics: Results from a large prospective observational study

P442 Endoscopic resection of visible precancerous lesions in patients with colonic Inflammatory Bowel Disease

P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

P444 A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes assessed

P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

P446 The INTESTINE study: INtended TEmporary STomas In crohN’s diseasE

P447 Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study

P448 Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn’s disease – an update from the TISKids study

P449 Minimally invasive IPAA in UC: Preliminary results from a referral center

P450 Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohort

P451 Early infliximab trough levels in paediatric IBD patients predict sustained remission

P452 Fecal Microbiota Transplantation Leads to Lower IBD Related Complications in Hospitalized Inflammatory Bowel Disease Patients with Clostridioides difficile Infection: A retrospective cohort study

P453 The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.

P454 No increased postoperative risk of venous thromboembolism nor infectious complications after JAK inhibitor exposure in patients with ulcerative colitis undergoing colectomy

P455 Comparison of two strategies for the management of post-operative recurrence in Crohn’s disease patients with one clinical risk factor: a multicentre IG-IBD study

P456 Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn's disease patients

P457 Treatment duration of ustekinumab in patients with Crohn’s disease (CD) and psoriasis (PSO) – real-world evidence from German claims data

P458 Low adherence to Mediterranean diet is associated with increased adipose tissue in patients with ulcerative colitis (UC) after pouch surgery: a cross sectional study

P459 Hospitalization, use of biologics and surgery rates in inflammatory bowel diseases: a single-center comparative analysis between public and private healthcare systems in a tertiary unit from Latin America

P460 Preoperative nutrition supplementation may prevent one-year endoscopic recurrence in Crohn’s disease patients

P461 Rapid response to appendectomy in the majority of patients with refractory Ulcerative Colitis

P462 Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders

P463 Crohn’s disease–associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study

P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis

P465 Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

P466 Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1

P467 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn’s disease - a nationwide cohort from the epi-IIRN

P468 Association of uncontrolled disease with quality of life and healthcare resource utilisation in Ulcerative Colitis patients treated with advanced therapy in the United States

P469 Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis

P470 Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn’s disease.

P471 A Transcriptome-dependent Prognostic Model of Response in Patients with Ulcerative Colitis

P472 Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective study

P473 Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn’s disease: Week 48 analyses from the phase 2 GALAXI 1 study

P474 Postoperative disease course after appendectomy as experimental treatment for patients with therapy refractory moderate to severe ulcerative colitis

P475 Infections and malignancies during anti-TNF therapy in IBD patients affect all age groups – results from a 13-yr real-world retrospective study

P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme

P477 Patient satisfaction and cost saving analysis of telemedicine in patients with inflammatory bowel disease.

P478 Platelet-related indicators for predicting vedolizumab response in patients with Ulcerative Colitis

P479 Reliability and responsiveness of histologic disease activity indices in Crohn’s Disease

P480 Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results From A Tertiary Inflammatory Bowel Disease Centre.

P481 Visceral fat to skeletal muscle area ratio predicts for Ustekinumab loss of response.

P482 The experiences of people with IBD and comorbid anxiety or depression and their views on an online intervention for people with long term conditions (COMPASS): A qualitative framework analysis

P483 Golimumab response in Ulcerative Colitis as early as week 2: What can we take from this?

P484 Inflammatory Bowel Disease exercise and diet habits (IBDeat) study: chronic metabolic disease risk factors among IBD patients in New Zealand

P485 An Assessment Of A Guided Self-Help and Patient Initiated Review Pathway for Ulcerative Proctitis

P486 Improving enhanced recovery after surgery (ERAS): the effect of a patient-centred mobile application on patient participation in colorectal surgery

P487 Anti TNF induced psoariasiform skin eruptions are increasing in in the biosimilar era – a descriptive study of drug induced skin manifestations and their management

P488 Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients’ acceptance

P489 Surgery for enterocutaneous fistula: the strongest predictor of postoperative mortality in Crohn’s disease patients

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

P493 QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

P494 Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study

P495 Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study

P496 Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy

P497 Is early bowel resection better than medical therapy for ileocolonic Crohn’s disease? A systematic review and meta-analysis

P498 Ustekinumab Real World Evidence Study (UndieS): study design with information about positioning and the choice of ustekinumab

P499 Exclusive enteral nutrition induces transmural healing in adults with active Crohn’s disease

P500 Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.

P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort

P502 Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost

P503 The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ

P504 Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells

P505 Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn’s disease: results from “long vedo” italian multicenter study

P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity

P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey

P508 Sarcopenia is associated with increased rates of infectious post-operative complications in Crohn’s disease patients

P509 Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.

P510 Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis.

P511 Evaluation of home faecal calprotectin testing to aid remote management and enhanced self-management of Inflammatory Bowel Disease.

P512 The counts of white blood cells are not predictive for long-term remission under treatment with thiopurines: a three year Japanese multi-center retrospective cohort study.

P513 Prospective study on patients’ satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel Disease

P514 Serum levels of Klotho in inflammatory bowel disease: an exploratory study

P515 Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternative

P516 Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study

P517 Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.

P518 Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)

P519 Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials

P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme

P521 Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitis

P522 Kono-S anastomosis reduces endoscopic and surgical post-operative recurrence in Crohn’s disease. The SuPREMe-CD Trial Update.

P523 Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn’s Colitis Care (CCCare): A real world observational study.

P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study

P525 Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysis

P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial

P527 Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis

P528 Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease Patients

P529 Year-two follow-up results of an observational study conducted in Crohn’s disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life setting

P530 The Burden on Cohabitants of Patients with Inflammatory Bowel Disease: A Cross-Sectional Study

P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases

P532 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy

P533 Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitis

P534 Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHAN

P535 COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy

P536 Is there any association between fat body mass and bone mineral density in patients with Inflammatory Bowel Disease?

P537 Prevalence of post-COVID-19 vaccination IBD flare-ups: a single-center prospective study.

P538 Suboptimal disease control is common in patients with Crohn’s perianal fistulas with capacity to optimise medical and surgical treatment in real-world experience: A cross-sectional analysis of baseline disease characteristics in the FINESS study

P539 Patient Preferences for Inflammatory Bowel Disease Treatments: Development of a European Preference Survey using a Discrete Choice Experiment

P540 The opinions and needs of patients living with refractory ulcerative proctitis, and the health care professionals who care for them; A Delphi consensus survey

P541 Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study.

P542 Short term efficacy, safety and thromboembolic risk of tofacitinib in moderate to severe Ulcerative Colitis

P543 Induction and maintenance of mucosal healing in Crohn's disease with ustekinumab in clinical practice – Results of a nationwide, prospective, multicenter study in Germany (MUCUS)

P544 Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn´s Disease patients

P545 Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

P547 Rate of Colectomy Increases within Twelve Months of Sequential Therapy for Ulcerative Colitis

P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

P549 One-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib Versus Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States

P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years

P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation.

P552 Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease Patients

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

P554 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials

P555 Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases

P556 Surgery in high-risk paediatric Crohn’s Disease treated with up-front anti-TNF agents and long-standing biologic therapy

P557 Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort study

P558 Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials

P559 SARS-CoV-2 vaccination does not increase the risk for flares in Inflammatory Bowel Disease patients

P560 Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial

P561 Risk of stoma formation in patients with Crohn’s perianal fistulas over a two decades period. A cohort study from a tertiary referral center.

P562 Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary center

P563 Monitoring of vedolizumab drug levels in a treat to target strategy for moderate-severe IBD (MOVE-IBD)

P564 vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn’s disease – a meta-analysis

P565 Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patients

P566 Colitis due to immunotherapy with anti-PD-1: a case series

P567 How can we predict the development of antibodies to infliximab in Crohn’s disease?

P568 Patients with ulcerative colitis after pouch surgery are at risk for low spinal bone mineral density: a cross sectional study

P569 Can thiopurines prevent crohn’s disease endoscopic postoperative recurrence in at risk patients?

P570 Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data from TOFA-UC, a SN-IBD Study

P571 Frequency and risk factors of advanced neoplasia in Korean IBD patients with Low Grade Dysplasia in previous surveillance

P572 Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomes

P573 Change in fatigue in patients with Ulcerative Colitis or Crohn’s disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patients

P574 Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

P576 Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD

P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis

P578 Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

P580 Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience

P581 Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn’s disease: European multicentre study with a propensity-score matched analysis

P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trial

P583 Tofacitinib for acute severe ulcerative colitis: a systematic review

P584 Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis

P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study

P586 Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study

P587 Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn’s disease – a systematic review.

P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

P589 Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapy

P590 ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in inducing Clinical and EnDoscopic remission in left-sided Ulcerative Colitis – A Randomized Clinical Trial

P591 Negative impact of high body mass index on the efficacy of anti-TNFα agents in patients with Inflammatory Bowel Disease

P592 Clinical evaluation of leukocytapheresis compared to vedolizumab in patients with Ulcerative Colitis with contraindications to anti-TNF-alpha: a single-centre experience

P593 Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases

P594 Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remission

P595 Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease

P596 Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort study

P597 Usefulness of histological monitoring in predicting relapse after de-escalation of thiopurines in Ulcerative Colitis

P598 The utility of the “Low Anterior Resection Syndrome SCORE” in assessing the postoperative outcomes of patients undergoing restorative proctocolectomy with ileal pouch anal-anastomosis for Ulcerative Colitis

P599 Similar efficacy of mesalazine in adult and elderly patients: post-hoc analysis of randomised non-inferiority trial of 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis

P600 Democratic deliberation to assess Veteran preferences for biosimilar medication switching for the treatment of Inflammatory Bowel Disease in a resource-conscious setting.

P601 Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project

P602 Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

P603 Real-world Scottish experience of anti-TNF therapy in paediatric Crohn’s disease 2016-2020 against the ECCO-ESPGHAN recommendations

P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study

P606 Significant regional differences in referral patterns for bowel resection in Crohn’s disease patients

P607 HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease

P608 Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysis

P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study

P610 Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)

P611 COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS. ANTI-TNFs IN CROHN’S DISEASE BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)

P612 Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study

P613 Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohort

P614 Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

P615 The safety and efficacy of ustekinumab combined with sphincter-preserving surgery for perianal fistulizing Crohn’s disease:a single-center retrospective study

P616 Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohort

P617 Dual biologic therapy in pediatric Inflammatory Bowel Disease

P618 Long-term real-world data of Ustekinumab in Ulcerative Colitis – the Stockholm Ustekinumab study – STOCUSTE

P619 Inflammatory bowel disease meets fertility: a physicians and patients survey

P620 Can ustekinumab trough and antidrug antibody levels post induction predict treatment failure?

P621 Combination treatment of biologics with immunomodulator increases risk of infection after discharge in biologics naive steroid refractory acute severe ulcerative colitis patient: A KASID multicenter study

P622 Change in Dietary Inflammatory Index Score in patients with Crohn’s disease and healthy volunteers following the Groningen Anti Inflammatory Diet (GrAID)

P623 Mucosal eosinophils as markers of post-induction vedolizumab response in paediatric Ulcerative Colitis

P624 Investigating the symptom burden among European patients with moderate-to-severe Crohn’s disease using a real-world survey

P625 Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis

[1] 2 > >>

ECCO'25 Abstracts

ECCO'24 Abstracts

Poster Presentations: Clinical: Therapy and Observation 2023